7-furoyloxy-4-phenylcoumarin | 94739-96-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 新黄酮类化合物
• 英文名称: 7-furoyloxy-4-phenylcoumarin
• 英文别名: 2-oxo-4-phenyl-2H-chromen-7-yl furan-2-carboxylate；(2-oxo-4-phenylchromen-7-yl) furan-2-carboxylate
• CAS: 94739-96-5
• 化学式: C₂₀H₁₂O₅
• 分子量: 332.312
• InChiKey: QMQDJJVJCMQHOT-UHFFFAOYSA-N

物化性质

• 沸点：
  517.5±50.0 °C(Predicted)
• 密度：
  1.353±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-furoyloxy-4-phenylcoumarin 以 乙醇 为溶剂， 反应 50.0h， 以120 mg的产率得到7-hydroxy-6-furoyl-4-phenylcoumarin
  参考文献：
  名称：

  Kulshrestha, S.K.; Dureja, P.; Mukerjee, S.K., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1984, vol. 23, # 11, p. 1064 - 1067

  摘要：

  DOI：
• 作为产物：
  描述：

  7-乙酰氧基-4-苯基-色烯-2-酮 在 吡啶 作用下， 以 乙醇 为溶剂， 反应 97.0h， 生成 7-furoyloxy-4-phenylcoumarin
  参考文献：
  名称：

  Kulshrestha, S.K.; Dureja, P.; Mukerjee, S.K., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1984, vol. 23, # 11, p. 1064 - 1067

  摘要：

  DOI：

文献信息

• PHYTOESTROGENIC FORMULATIONS FOR ALLEVIATION OR PREVENTION OF MENOPAUSAL SYMPTOMS
  申请人：Brinton Roberta Diaz

  公开号：US20100113586A1

  公开（公告）日：2010-05-06

  Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with pre menopause, menopause, and/or post menopause are described herein. These select phytoestrogen formulations are composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotection mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. The formulations can be administered enterally, transdermally, transmucosally, intranasally or parenterally. The formulations preferably contain combinations of compounds, and can be formulated for daily, sustained, delayed or weekly/monthly administration. In a preferred embodiment, these are administered to women who are in menopause or post menopausal, most preferably early in menopausal.
• PHYTOESTROGENIC FORMULATIONS FOR ALLEVIATION OR PREVENTION OF HAIR LOSS
  申请人：Brinton Roberta Diaz

  公开号：US20110091435A1

  公开（公告）日：2011-04-21

  Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with hair loss or prostate cancer/prostate hypertrophy are described herein. These select phytoestrogen formulations are preferably composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in non-reproductive tissues including brain.
• US8552057B2
  申请人：——

  公开号：US8552057B2

  公开（公告）日：2013-10-08
• US8680140B2
  申请人：——

  公开号：US8680140B2

  公开（公告）日：2014-03-25
• Kulshrestha, S.K.; Dureja, P.; Mukerjee, S.K., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1984, vol. 23, # 11, p. 1064 - 1067
  作者：Kulshrestha, S.K.、Dureja, P.、Mukerjee, S.K.

  DOI：——

  日期：——